

Gibson Dunn Advises 89bio on Its Up to \$3.5 Billion Sale to Roche Holdings

Firm News | September 19, 2025

Gibson Dunn is advising 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, on its up to \$3.5 billion sale to Roche Holdings, Inc. Our corporate team is led by partners Branden Berns, Ryan Murr, and Evan D'Amico and includes partners Karen Spindler, Melanie Neary, and George Sampas and associates Jonathan Sapp, Ayushi Sutaria, Lauren Navarro, and Risa Nakagawa. Partner Sean Feller and of counsel Alli Balick are advising on employee compensation and benefits matters; partner Pamela Lawrence Endreny and associate Bree Gong are advising on tax matters; and Michael J. Perry is advising on U.S. and foreign antitrust and competition matters.

Related People

[Branden C. Berns](#)

[Ryan A. Murr](#)

[Evan M. D'Amico](#)

[Karen A. Spindler](#)

[Melanie E. Neary](#)

[George Sampas](#)

[Jonathan R. Sapp](#)

[Ayushi Sutaria](#)

[Lauren Navarro](#)

[Risa Nakagawa](#)

[Sean C. Feller](#)

[Alli Balick](#)

[Pamela Lawrence Endreny](#)

[Bree Gong](#)

[Michael J. Perry](#)

Related Capabilities

[Mergers and Acquisitions](#)

[Life Sciences](#)

[Executive Compensation and Employee Benefits](#)

[Tax](#)

[Antitrust and Competition](#)